Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Belite Bio, Inc. ADR ( (BLTE) ) has issued an announcement.
On November 10, 2025, Belite Bio reported its financial results for the third quarter of 2025 and provided a corporate update. The company completed enrollment in its pivotal phase 3 PHOENIX trial for geographic atrophy and the DRAGON trial for Stargardt disease, with final topline data expected in Q4 2025. Regulatory agencies in China and the UK have accepted applications for Tinlarebant based on interim analysis results. Financially, Belite Bio completed a $15 million registered direct offering and a $125 million private placement, strengthening its position to advance Tinlarebant towards regulatory milestones.
The most recent analyst rating on (BLTE) stock is a Buy with a $132.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.
Spark’s Take on BLTE Stock
According to Spark, TipRanks’ AI Analyst, BLTE is a Neutral.
Belite Bio faces significant financial challenges with no revenue and increasing losses, impacting its overall score. Technical indicators show neutral momentum, and valuation is unattractive with negative earnings. However, the earnings call highlights clinical advancements and financial stability, providing a positive outlook in the long term despite current financial difficulties.
To see Spark’s full report on BLTE stock, click here.
More about Belite Bio, Inc. ADR
Belite Bio, Inc is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs. The company is working on treatments for conditions like Stargardt disease and geographic atrophy, with its lead product candidate, Tinlarebant, being developed as an oral retinol binding protein 4 antagonist.
Average Trading Volume: 65,604
Technical Sentiment Signal: Buy
Current Market Cap: $3.69B
For a thorough assessment of BLTE stock, go to TipRanks’ Stock Analysis page.